How to Become a STELFONTA® (tigilanol tiglate injection) SUPERSTAR: Part 1 of 4

Overview:

This is the first part of a four-part series; this session introduces the fundamental aspects of STELFONTA^®, focusing on its mechanism of action, efficacy, and evidence supporting its use. Through detailed case studies, including Brooklyn's 8th MCT and other real-life examples, participants will learn about indication, case selection, and cytologic grading for MCT. The session will also cover practical steps for starting out with STELFONTA^® and advancing its application in veterinary practice.

Learning Objectives:

• Understand the mechanism of action of STELFONTA^® (tigilanol tiglate injection).
• Review the efficacy and evidence supporting the use of STELFONTA^® in treating canine mast cell tumors.
• Identify appropriate indications and case selection criteria for STELFONTA^® use.
• Learn about cytologic grading and its importance in the treatment process.
• Gain insights into starting out with STELFONTA^® and advancing its use through real-life case examples

IMPORTANT SAFETY INFORMATION
Accidental self-injection of STELFONTA® (tigilanol tiglate injection) may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary. In dogs, do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock. Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. For full prescribing information, contact VIRBAC at 1-800-338-3659 or visit https://vet-us.virbac.com/stelfonta.